Literature DB >> 12782438

Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.

Manish Srivastava1, Norman Brito-Dellan, Mellar P Davis, Marie Leach, Ruth Lagman.   

Abstract

Nausea and vomiting are difficult symptoms to manage in patients with advanced cancer. Several classes of antiemetics are available, including phenothiazines, butyrophenones, substituted benzamides and selective serotonin antagonists, as well as corticosteroids. Most patients will respond to either single agents or combinations that frequently include corticosteroids. A minority of patients will have nausea that fails to respond. The atypical antipsychotic, olanzapine, relieves nausea in some patients failing to respond to the usual antiemetics. Two case reports are presented and the rationale for olanzapine's benefit is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782438     DOI: 10.1016/s0885-3924(03)00143-x

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  28 in total

1.  Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.

Authors:  Ronald Chow; David G Warr; Rudolph M Navari; May Tsao; Marko Popovic; Leonard Chiu; Milica Milakovic; Henry Lam; Carlo DeAngelis
Journal:  Support Care Cancer       Date:  2018-05-23       Impact factor: 3.603

2.  Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.

Authors:  Sierra Vig; Laurel Seibert; Myke R Green
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-31       Impact factor: 4.553

3.  The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Veerisa Vimolchalao; Siwat Sakdejayont; Ploytuangporn Wongchanapai; Shama Sukprakun; Pattama Angspatt; Wilai Thawinwisan; Piyachut Chenaksara; Virote Sriuranpong; Chanida Vinayanuwatikun; Napa Parinyanitikun; Nattaya Poovorawan; Suebpong Tanasanvimon
Journal:  Int J Clin Oncol       Date:  2019-11-27       Impact factor: 3.402

Review 4.  Nausea and Vomiting in Advanced Cancer.

Authors:  Rudolph M Navari
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

5.  Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.

Authors:  Ali Alkan; Özgür Tanrıverdi
Journal:  Support Care Cancer       Date:  2019-10-24       Impact factor: 3.603

Review 6.  Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.

Authors:  Christopher M Hocking; Ganessan Kichenadasse
Journal:  Support Care Cancer       Date:  2014-02-13       Impact factor: 3.603

7.  The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Rudolph M Navari; Cindy K Nagy; Sarah E Gray
Journal:  Support Care Cancer       Date:  2013-01-12       Impact factor: 3.603

8.  Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.

Authors:  Rudolph M Navari; Marie C Brenner
Journal:  Support Care Cancer       Date:  2009-09-11       Impact factor: 3.603

Review 9.  [New antiemetic strategies - not only in oncology].

Authors:  K Jordan; F Müller; H J Schmoll
Journal:  Internist (Berl)       Date:  2009-07       Impact factor: 0.743

10.  Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.

Authors:  Lijun Tan; Jiangtao Liu; Xiuli Liu; Jie Chen; Zhijun Yan; Huifen Yang; Daxin Zhang
Journal:  J Exp Clin Cancer Res       Date:  2009-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.